0925 ET - Restaurant executives say they haven't seen a big impact on their sales from GLP-1 weight-loss drugs, but they are prompting some concerns. Darden Restaurants says it's watching if the drugs curb sales at its fine-dining brands, which tend to attract higher-income consumers who could more readily afford the drugs. Fiscal 2Q same-store sales at Darden's fine-dining segment fell 5.8% as consumers who traded up to the brands last year are now more price conscious, shifting back to more affordable casual-dining, the company says. (heather.haddon@wsj.com; @heatherhaddon)
(END) Dow Jones Newswires
December 19, 2024 09:25 ET (14:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。